Content specific to this active ingredient… Drug Information Prescribing and patient information from leading authorities Drug Master Files Type 2 master files on file at the FDA Safety Information For prescription drugs containing this active ingredient Exclusivity Patent and market exclusivity data Federal Register FR search results for this API FDA Approved Labelling Information found in this drug's package inserts Research Links Chemical identification and research citations Title 21 Code of Federal Regulations FDA regulations for this API

FDA Approval Activities for this Drug… Maxalt (rizatriptan benzoate) Tablets & Maxalt-MLT (orally disintegrating tablet), 5 and 10 mg, Merck NDA 20-864/S8 & 20-865/S9 4/22/02 5/2/02 | Maxalt (rizatriptan benzoate) Tablets & Maxalt-MLT (orally disintegrating tablet), 5 and 10 mg, Merck NDA 20-864 & 20-865 6/29/98 6/30/98 6/30/98 4/8/99 | Maxalt Indication: Migraine | Maxalt (rizatriptan)5 and 10 mg, . Merck & Co., NDA 20-865/S-001 NDA 20-864/S-003 | Rizatriptan Benzoate Orally Disintegrating Tablets, Mylan Pharmaceuticals, Tentative Approval | Rizatriptan Benzoate Tablets, Teva Pharma, Tentative Approval | Rizatriptan Benzoate Tablets, Sandoz Inc., Tentative Approval | Maxalt (rizatriptan benzoate) Tablets, Merck Sharp & Dohme Corp., Labeling Revision | Maxalt-MLT (rizatriptan benzoate) Orally Disintegrating Tablets, Merck Sharp & Dohme Corp., Labeling Revision | Rizatriptan Benzoate Orally Disintegrating Tablets, Sandoz, Inc., Tentative Approval | Rizatriptan Benzoate Tablets, Cipla Ltd., Tentative Approval ^ FDA's latest approval appears at the bottom of this list. ^                                                                       A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U-Z Health Topics | For Industry | DMF Index | Pharma Job Search | Pharma Company News | Best Phone © 2012 Betterchem.com